Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

Table 6 Hearing loss 3 months post first fitting compared to baseline: a descriptive subgroup analysis of the primary endpoint by age and residual hearing—ITT set

Baseline factor	Subgroup	Treatment	Number	Mean HL	Std. Dev.
Age	Younger or equal to 55 years	Placebo	11	35.91	17.72
	Younger or equal to 55 years	ACEMg	15	21.33	17.97
	Older than 55 years	Placebo	13	25.38	12.82
	Older than 55 years	ACEMg	10	33.00	15.13
Residual hearing at 500 Hz	Less or equal to 65 dB	Placebo	9	37.22	21.23
	Less or equal to 65 dB	ACEMg	8	24.38	18.41
	More than 65 dB	Placebo	15	26.00	10.21
	More than 65 dB	ACEMg	17	26.76	17.67

ISSN: 1745-6215